Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins
- 1 September 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 5 (sup1) , S29-S36
- https://doi.org/10.1517/14712598.5.1.s29
Abstract
Recombinant monoclonal antibodies and IgG Fc-containing fusion proteins represent major therapeutic advances in many diseases. However, despite their similarity with endogenous IgG, some patients respond to the treatment whilst others do not; thus raising the question of the origin of this variability. Some variability factors are now identified, of genetic origin or not, which influence either pharmacokinetics or pharmacodynamics of these drugs. Known variability factors are reviewed and classified according to their relationship with the paratope (antigen binding site) of the antibodies, with other parts of the IgGs (mostly Fc) or with IgG epitopes (antigenic motifs).Keywords
This publication has 45 references indexed in Scilit:
- Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative DisordersJournal of Clinical Oncology, 2005
- Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s MacroglobulinemiaJournal of Clinical Oncology, 2005
- FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemiaBlood, 2005
- The influence of genetic variation in the HLA–DRB1 and LTA–TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanerceptArthritis & Rheumatism, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaBlood, 2004
- Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIaJournal of Molecular Biology, 2004
- Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood, 2003
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002
- The pharmacological basis of anti-IgE therapyNature Biotechnology, 2000